Taho Pharmaceuticals Ltd. (TPEX:6467)

Market Cap	6.83B +126.2%
Revenue (ttm)	5.42M +80.8%
Net Income	-232.53M
EPS	-4.49
Shares Out	52.37M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	371,564
Open	129.50
Previous Close	129.50
Day's Range	128.50 - 134.50
52-Week Range	45.60 - 208.50
Beta	-32.44
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Taho Pharmaceuticals

Taho Pharmaceuticals Ltd., a commercial-stage pharmaceutical company, focuses on the development of drug delivery systems in transdermal and transmucosal systems in Taiwan. The company offers TAH4411 Ondansetron ODF, a selective serotonin 5HT3 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Its pipeline includes TAH3311 Apixaban oral film, which is in phase III; TAH3341, an anticoagulant apixaban ODF extended-release film, which is in preclinical stage. The company also develops TAH2211 Buprenorphine/Naloxone ...

• Industry: Pharmaceutical Preparations
• Founded: 2010
• Employees: 35
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6467

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 19, 2026

Data Sources Report a data error